Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer

European Journal of Cancer

Volumn 36, Issue SUPPL. 2, 2000, Pages 17-25

  Bellmunt, J ^a   Guillem, V ^b   Paz Ares, L ^c   Gonzalez Larriba J L ^d   Carles, J ^e   Albanell, J ^a   Tabernero, J M ^a   Cortes Funes H ^c   Baselga, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL DEL MAR   (Spain)

Author keywords

Advanced bladder cancer; Carboplatin; CISCA; Cisplatin; Gemcitabine; M VAC; Paclitaxel; Three drug regimen chemotherapy; Transitional cell carcinoma; Two drug regimen chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADVANCED CANCER; ASTHENIA; BLADDER CANCER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT TUMOR; VOMITING;

EID: 0033922030     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(00)00081-2     Document Type: Review

References (67)

1. Roth BJ, Bajorin D. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol 1995, 153, 894-900.
2. Sher HI, Shipley WU, Herr HW. Cancer of the bladder. In De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott-Raven, 1997, 1300-1322.
3. Yagoda A. Chemotherapy of urothelial tract tumors. Cancer 1987, 60(Suppl. 3), 574-585.
4. Yagoda A. Phase II trials in patients with urothelial tumors: Memorial Sloan-Kettering Cancer Center. Cancer Chemother Pharmacol 1993, 11, 9-12.
5. Herr HW. Cis-diamminedichloride platinum II in the treatment of advanced bladder cancer. J Urol 1980, 123, 853-857.
6. Peters PC, O'Neill MR. Cisdiammine-dichloroplatinum as a therapeutic agent in metastatic transitional cell carcinoma. J Urol 1980, 123, 375-377.
7. Rossof AM, Talley RW, Stephens RL. Phase II evaluation of cisdichlorodiammineplatinum II in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group study. Cancer Treat Rep 1979, 63, 1557-1564.
8. Loehrer PJ, Einhorm LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study. J Clin Oncol 1992, 10, 1066-1073.
9. Troner M, Birch R, Omura GA, et al. Phase III comparison of cisplatin alone versus cisplatin, doxorubicin, and cyclophosphamide in the treatment of bladder cancer: a Southeastern Cancer Study Group trial. J Urol 1987, 137, 660-762.
10. Seidman AD, Scher HI, Heinemann MH, et al. Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer 1991, 68, 2561-2565.
11. Witte RS, Elson P, Bono B, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997, 15, 589-593.
12. Witte RS, Elson P, Chandler J, et al. An Eastern Cooperative Oncology Group phase II trial of trimetrexate in treatment of advanced urothelial carcinoma. Cancer 1994, 73, 688-691.
13. Lorusso V, Pollera CF, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998, 34, 1208-1212.
14. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997, 15, 3394-3398.
15. Moore MJ, Tannock I, Ernst S, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997, 15, 3441-3445.
16. Roth B, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the ECOG. J Clin Oncol 1994, 12, 2264-2270.
17. Fuchs DA, Johnson RK. Cytologic evidence that Taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep 1978, 62, 1219-1222.
18. Niell HB, Rangel C, Miller A, et al. The activity of antimicrotubular agents in human bladder tumor cell lines (HBTCL). Proc Am Assoc Cancer Res 1993, 34, 202 (A 1207).
19. Rangel C, Niell H, Miller A, et al. Taxol and Taxotere in bladder cancer: in vitro activity and urine stability. Cancer Chemother Pharmacol 1994, 33, 460-464.
20. Dreicer R, Gustin DM, See WA, et al. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 1996, 156, 1606-1608.
21. Pollera CF, Ceribelli A, Grecco M, et al. Weekly gemcitabine in advanced bladder cancer. A preliminary report from a phase I study. Ann Oncol 1994, 5, 182-184.
22. Geller NL, Sternberg CN, Penenberg D, et al. Prognostic factor for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 1991, 67, 1525-1531.
23. Bajorin D, Dodd P, Mazumdar M, et al. Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999, 17, 3173-3181.
24. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985, 133, 403-407.
25. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989, 64, 2448-2458.
26. Harker WG, Meyers FJ, Freiha FS, et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group Study. J Clin Oncol 1985, 3, 1463-1470.
27. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988, 139, 461-469.
28. Boutan-Laroze A, Mabjoubi M, Droz JP, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. Eur J Cancer 1991, 27A, 1690-1694.
29. Igawa M, Obkuchi T, Ueki T, et al. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 1990, 144, 662-665.
30. Tannock I, Gospodarowicz M, Connolly J, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol 1989, 142, 289-292.
31. Fossa SD, Sternberg CN, Scher HI, et al. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. Br J Cancer 1996, 74, 1492-1498.
32. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990, 8, 1050-1055.
33. Bellmunt J, Ribas A, Eres N, et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997, 80, 1966-1972.
34. Mead GM, Crook AM, Russell JM, et al. An MRC randomized trial comparing MV (methotrexate and vinblastine) with CMV (cisplatin + MV) for metastatic transitional cell cancer (TCC). Proc Am Soc Clin Oncol 1996, 15, 241a (A 600).
35. Saxman SB, Propert KJ, Einhorn LH, et al. Long term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study. J Clin Oncol 1997, 15, 2564-2569.
36. Calvert HA, Harland SJ, Newell DR, et al. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev 1985, 12, 51-57.
37. BellmuntJ, Albanell J, Gallego O, et al. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 1992, 70, 1974-1979.
38. Waxman J, Abel P, James N, et al. New combination chemotherapy programme for bladder cancer. Br J Urol 1989, 63, 68-71.
39. Small EJ, Fippin LJ, Ernest ML, et al. A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 1996, 78, 1775-1780.
40. Klocker J, Pont J, Schumer J, et al. Carboplatin, methotrexate and vinblastine (Carbo-MV) for advanced urothelial cancer. Am J Clin Oncol 1991, 14, 328-330.
41. Waxman J, Barton C. Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev 1993, 19(Suppl. C), 21-25.
42. Boccardo F, Pace M, Guarneri D, et al. Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial. Cancer 1994, 73, 1932-1936.
43. Petrioli R, Frediani B, Manganelli A, et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 1996, 77, 344-351.
44. Murphy BA, Johnson DR, Smith J, et al. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer. Proc Am Soc Clin Oncol 1996, 15, 245a (A 617).
45. Dreicer R, Roth B, Lipsitz S, et al. E2895 cisplatin and paclitaxel in advanced carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group (ECOG). Proc Am Soc Clin Oncol 1998, 17, 320a (A 1233).
46. Burch PA, Richardson RL, Cha SS, et al. Phase II trial of combination paclitaxel and cisplatin in advanced urothelial carcinoma. Proc Am Soc Clin Oncol 1999, 18, 329a (A 1266).
47. Sengelov L, Kamby C, Lund B, et al. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol 1998, 16, 3392-3397.
48. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995, 13, 1860-1870.
49. Vaughn DJ, Malkowicz SB, Zoltick B, et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 1998, 16, 255-260.
50. Redman BG, Smith DC, Flaherty L, Du W, Hussain M. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 1998, 16, 1844-1848.
51. Zielinski CC, Schnack B, Grbovic M, et al. Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial. Br J Cancer 1998, 78, 370-374.
52. Droz JP, Mottet N, Prapotich D, et al. Phase II study of Taxol (paclitaxel) and carboplatin in patients with advanced transitional-cell carcinoma of the urothelium: preliminary results. Proc Am Soc Clin Oncol 1998, 17, 316a (A 1219).
53. Bauer J, Stadler M, Roth A, et al. Phase II trial of paclitaxel (P) plus carboplatin (C) in advanced urothelial tract cancer (UTC). Proc Am Soc Clin Oncol 1998, 17, 326a (A 1255).
54. Small EJ, Lew D, Petrylak DP, et al. Carboplatin and paclitaxel (Carbo/Tax) for advanced transitional cell carcinoma (TCC) of the urothelium. Proc Am Soc Clin Oncol 1999, 18, 333a (A 1280).
55. von der Maase H, Andersen L, Crino L, Weinknecht S, Dogliotti L. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium. Ann Oncol 1999, 10, 1461-1465.
56. Kaufman D, Stadler W, Carducci M, et al. Gemcitabine (GEM) plus cisplatin (CDDP) in metastatic transitional cell carcinoma (TCC): final results of a phase II study. Proc Am Soc Clin Oncol 1998, 17, 320a (A 1235).
57. Moore MJ, Winquist E, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999, 17, 2876-2880.
58. Bellmunt J, Guillem V, Paz-Ares JL, et al. A phase II trial of paclitaxel, cisplatin and gemcitabine (TCG) in patients (pts) with advanced transitional cell carcinoma (TCC) of the urothelium. Proc Am Soc Clin Oncol 1999, 18, 332a (A 1279).
59. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of Taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991, 9, 1692-1703.
60. Rothenberg ML, Sharma A, Weiss GR, et al. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol 1998, 9, 733-738.
61. Seidman AD, Hudis CA, Albanell J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998, 16, 3353-3361.
62. Frasci G, Panza N, Comella P, et al. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. J Clin Oncol 1999, 17, 2316-2325.
63. Sørensen JB, Stenbygaard LE, Dombernowsky P, Hansen HH. Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small cell lung cancer. Ann Oncol 1999, 10, 1043-1049.
64. Vaishampayan U, Smith D, Redman B, et al. Phase II evaluation of carboplatin, paclitaxel and gemcitabine in advanced urothelial carcinoma. Proc Am Soc Clin Oncol 1999, 18, 333a (A 1282).
65. Bajorin DF, McCaffrey JA, Hilton S, et al. Treatment of patients with transitional cell carcinoma of the urothelial tract with ifosfamide, paclitaxel and cisplatin: a phase II trial. J Clin Oncol 1998, 16, 2722-2727.
66. Tu SM, Hossan E, Amato R, et al. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol 1995, 154, 1719-1722.
67. Meyers FJ, Edelman MJ, Houston J, Lauder I. Phase I/II trial of paclitaxel, carboplatin and methotrexate in advanced transitional cell carcinoma. Proc Am Soc Clin Oncol 1998, 17, 317a (A 1222).